Figure 2. Persister cells are vulnerable to GPX4 inhibition.
Breast (BT474), melanoma (A375), lung (PC9) and ovarian (Kuramochi) cancer parental or persister cells (see Methods) were treated with GPX4 inhibitor RSL3 (a-d) or ML210 (e-h) for three days. i, A375 GPX4 WT or KO persister cells and j, parental cells with ferrostatin-1 withdrawn for three days. Data are plotted as means and error bars represent standard deviation. a-h, n = 2, and i, j, n = 3 biologically independent samples. From two-tailed t tests,*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, P > 0.05. All data are representative of two separate experiments.